One of the starkest realities facing the contemporary research community is the paucity of experienced investigators involved in translational pancreatic cancer research. The goal of the Career Developmental Program (CDP) is to attract, develop, and monitor the most promising investigators for translational research in pancreatic cancer. The CDP is targeted to both junior faculty and early mid-career faculty at any Mayo Clinic campus who will commit to mentored career development. We have attracted and nurtured individuals who are now committed to a pancreatic cancer research career. One of our past CDP awardees (Dr. Robert McWilliams) has developed successfully to become a Co-leader in a full translational research project in this current competing renewal application. The corps of senior pancreatic cancer researchers at Mayo Clinic, combined with highly productive investigators in other areas of cancer research, form mentoring teams. Mentoring is accompanied by close oversight by the SPORE leadership team. The Director of the CDP will report to the SPORE Director and the SPORE Steering Committee. Mayo Clinic has, by its seamless blend of patient care and basic and applied research facilities, an environment conducive to this type of mentored translational research. Because Mayo Clinic is competitive in recruiting faculty, there is a continuous pool of early but outstanding scientists and clinicians (including talented female and minority investigators) who need an impetus such as that offered by our SPORE?s proposed CDP to engage in translational research with a focus on pancreatic cancer. We will continue to implement our formal mechanisms for recruiting, selecting and evaluating awardees, and will ensure that awardees are integrated into the SPORE research environment. In all cases, we expect that recipients in the CDP will build upon the resources allocated to them to develop independent funding in pancreatic cancer research. The explicit expectation is that the awardees will utilize the resources made available to them for the development of independent research programs and acquisition of independent funding in breast cancer research. One annual award for up to $100,000 will be made ($50K from the SPORE grant, matched by Mayo Clinic Cancer Center support).
The Career Development Program will use SPORE and Cancer Center matching funds to support one awardee per year. The program seeks to attract both early- or mid-career investigators who are new to pancreatic cancer and who will make a career commitment to translational research in this cancer.
|Chini, Claudia C S; Espindola-Netto, Jair M; Mondal, Gourish et al. (2016) SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res 22:2496-507|
|Murphy, Stephen J; Hart, Steven N; Halling, Geoffrey C et al. (2016) Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. Cancer Res 76:749-61|
|Chaiteerakij, Roongruedee; Petersen, Gloria M; Bamlet, William R et al. (2016) Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. J Clin Oncol 34:1898-904|
|Cao, H; Eppinga, R D; Razidlo, G L et al. (2016) Stromal fibroblasts facilitate cancer cell invasion by a novel invadopodia-independent matrix degradation process. Oncogene 35:1099-110|
|Hu, Chunling; Hart, Steven N; Bamlet, William R et al. (2016) Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev 25:207-11|
|McWilliams, Robert R; Maisonneuve, Patrick; Bamlet, William R et al. (2016) Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Pancreas 45:311-6|
|Carr, Ryan M; Fernandez-Zapico, Martin E (2016) Pancreatic cancer microenvironment, to target or not to target? EMBO Mol Med 8:80-2|
|Wang, Jianbo; Galvao, Joana; Beach, Krista M et al. (2016) Novel Roles and Mechanism for KrÃ¼ppel-like Factor 16 (KLF16) Regulation of Neurite Outgrowth and Ephrin Receptor A5 (EphA5) Expression in Retinal Ganglion Cells. J Biol Chem 291:18084-95|
|Lopez, Angelica P; Kugelman, Jeffrey R; Garcia-Rivera, Jose et al. (2016) The Structure-Specific Recognition Protein 1 Associates with Lens Epithelium-Derived Growth Factor Proteins and Modulates HIV-1 Replication. J Mol Biol 428:2814-31|
|Lakshminarayanan, Vani; Supekar, Nitin T; Wei, Jie et al. (2016) MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS One 11:e0145920|
Showing the most recent 10 out of 242 publications